Aratana Therapeutics (PETX) Given Hold Rating at Stifel Nicolaus

Stifel Nicolaus restated their hold rating on shares of Aratana Therapeutics (NASDAQ:PETX) in a research note issued to investors on Monday morning. They currently have a $6.00 price objective on the biopharmaceutical company’s stock.

PETX has been the topic of a number of other research reports. Jefferies Group set a $9.00 price target on Aratana Therapeutics and gave the stock a buy rating in a report on Thursday, November 16th. ValuEngine lowered Aratana Therapeutics from a sell rating to a strong sell rating in a report on Friday, September 1st. Zacks Investment Research raised Aratana Therapeutics from a hold rating to a buy rating and set a $7.75 price target on the stock in a report on Thursday, November 9th. HC Wainwright began coverage on Aratana Therapeutics in a report on Friday, November 17th. They set a buy rating and a $10.00 price target on the stock. Finally, Lake Street Capital lowered their price target on Aratana Therapeutics from $15.00 to $10.00 and set a buy rating on the stock in a report on Friday, August 25th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $8.55.

Aratana Therapeutics (NASDAQ PETX) traded down $0.13 during midday trading on Monday, hitting $5.60. The company had a trading volume of 1,197,400 shares, compared to its average volume of 417,089. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.08 and a current ratio of 3.42. Aratana Therapeutics has a 52-week low of $4.97 and a 52-week high of $8.63.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.03. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The firm had revenue of $6.16 million for the quarter, compared to analyst estimates of $6.47 million. During the same quarter last year, the company posted ($0.38) earnings per share. The business’s revenue was up 1440.0% on a year-over-year basis. analysts predict that Aratana Therapeutics will post -1.03 earnings per share for the current fiscal year.

In other Aratana Therapeutics news, COO Brent Standridge sold 10,000 shares of Aratana Therapeutics stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $6.11, for a total value of $61,100.00. Following the sale, the chief operating officer now owns 70,267 shares of the company’s stock, valued at approximately $429,331.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of Aratana Therapeutics stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $5.70, for a total value of $5,075,941.20. The disclosure for this sale can be found here. Insiders sold a total of 1,117,032 shares of company stock worth $6,559,891 in the last ninety days. 5.20% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently made changes to their positions in the business. Janney Montgomery Scott LLC boosted its holdings in Aratana Therapeutics by 7.9% in the 2nd quarter. Janney Montgomery Scott LLC now owns 16,400 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 1,200 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in Aratana Therapeutics by 17.9% in the 1st quarter. Metropolitan Life Insurance Co. NY now owns 25,619 shares of the biopharmaceutical company’s stock valued at $136,000 after purchasing an additional 3,883 shares in the last quarter. Voya Investment Management LLC boosted its holdings in Aratana Therapeutics by 22.7% in the 2nd quarter. Voya Investment Management LLC now owns 19,530 shares of the biopharmaceutical company’s stock valued at $141,000 after purchasing an additional 3,610 shares in the last quarter. Ray Gerald L & Associates Ltd. boosted its holdings in Aratana Therapeutics by 0.8% in the 2nd quarter. Ray Gerald L & Associates Ltd. now owns 24,100 shares of the biopharmaceutical company’s stock valued at $174,000 after purchasing an additional 200 shares in the last quarter. Finally, ProShare Advisors LLC boosted its holdings in Aratana Therapeutics by 7.2% in the 2nd quarter. ProShare Advisors LLC now owns 25,322 shares of the biopharmaceutical company’s stock valued at $183,000 after purchasing an additional 1,709 shares in the last quarter. 73.76% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://sportsperspectives.com/2017/12/19/aratana-therapeutics-petx-given-hold-rating-at-stifel-nicolaus.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Analyst Recommendations for Aratana Therapeutics (NASDAQ:PETX)

Receive News & Ratings for Aratana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aratana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply